Table 4.

MCII cutpoints with 2 methodological approaches for changes in health-related quality of life and health status measures after 3 months of DMARD treatment in patients with RA, PsA, and AS.

75% Sensitivity Cutpoint80% Specificity CutpointReceiver-operating Characteristic (ROC) Curves
Area Under the Curve95% CI
Pain VAS
Patient global VAS
  • MCII: Minimal Clinically Important Improvement; DMARD: diseasemodifying antirheumatic drug; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; PASS: Patient Acceptable Symptom State; MHAQ: Modified Health Assessment Questionnaire; VAS: visual analog scale; EQ-5D: EuroQol-5 Dimensions; SF-6D: Short-Form-6 Dimensions.